Need help finding what you are looking for?
Contact Us
PUBLISHER: KuicK Research | PRODUCT CODE: 1388514
PUBLISHER: KuicK Research | PRODUCT CODE: 1388514
Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029
PUBLISHED:
PAGES: 1800 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
“Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029” Reports Findings & Highlights:
- Global Peptide Therapeutics Market Opportunity: > USD 80 Billion By 2029
- Global & Regional Peptide Therapeutics Market Outlook
- Insight On Peptides In Clinical Trials By Country, Indication & Phase: > 900 Peptides In Trials
- Comprehensive Insight On Peptides Drugs Available in Market: > 200 Peptides
- Marketed Peptide Drugs Insight: Patent, Availability, Cost, Dosage, & Sales Insight
- Global, Regional, Annual & Quarterly Sales Insights
- Peptide Therapeutics Development Technologies Platform
- Global Peptide Drugs Clinical Research & Market Trends by Indication
In the dynamic pharmaceutical landscape, peptide drugs stand out as an indicator of innovation and therapeutic potential. These exception therapeutic agents have received a lot of interest due to their wide range of applications and distinct advantages. Peptide drugs provide a precise and personalized approach to therapy, from treating metabolic abnormalities to tackling complex diseases like cancer. As a result, it has become important for the pharmaceutical industry to understand the growing significance of peptides in the market to exploit their full potential, and also the revolutionary influence they are poised to have in the constantly evolving environment of healthcare.
Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.
The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.
The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.
The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.
Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides' adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients' medical diverse needs.
In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative pains a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.
Table of Contents
1. Introduction to Peptide Drugs
- 1.1. History, Development & Evolution
- 1.2. Approved Peptide Drugs
2. Peptide Drugs - Therapeutic, Diagnostic & Theranostic Potential & Market Implications
- 2.1. Therapeutic Potential & Market Implications
- 2.2. Diagnostic Potential & Market Implications
- 2.3. Theranostic Potential & Market Implications
3. Global Peptide Drugs Clinical Research & Market Trends by Indication
- 3.1. Inheritable Genetic Diseases
- 3.2. Cancer
- 3.3. Microbial Infections
- 3.4. Autoimmune Disorders
- 3.5. Metabolic Disorders
- 3.6. Neurodegenerative Diseases
4. Peptide Based Therapeutic Approaches
- 4.1. Peptide Hormone Drugs
- 4.2. Peptide Drug Conjugates
- 4.3. Peptide Vaccines
- 4.4. Peptide Agonists
- 4.5. Peptide Aptamers
- 4.6. Peptide Antibody
5. Global Peptide Therapeutics Market Outlook
- 5.1. Current Market Trends & Drivers
- 5.2. Future Growth Avenues
6. Peptide Therapeutics Market Landscape by Region
- 6.1. US
- 6.2. EU
- 6.3. China
- 6.4. Japan
- 6.5. South Korea
- 6.6. UK
- 6.7. India
- 6.8. Middle East
- 6.9. Canada
- 6.10. Australia
7. Global Peptide Therapeutics Clinical Trials Overview
- 7.1. By Country
- 7.2. Indication
- 7.3. Phase
- 7.4. Priority Status
- 7.5. Therapy Class
8. Marketed Peptide Drugs Insight - Patent, Availability, Cost, Dosage, & Sales Insight
- 8.1. Bylvay
- 8.1.1. Overview
- 8.1.2. Pricing & Dosage Analysis
- 8.1.3. Sales Insight
- 8.2. Parsabiv
- 8.2.1. Overview & PatentS Insight
- 8.2.2. Pricing & Dosage Analysis
- 8.2.3. Sales Insight
- 8.3. Bydureon BCise
- 8.3.1. Overview & Patent Insight
- 8.3.2. Pricing & Dosage Analysis
- 8.3.3. Sales Insight
- 8.4. Linzess
- 8.4.1. Overview & Patent Insight
- 8.4.2. Pricing & Dosage Insight
- 8.4.3. Sales Insight
- 8.5. Increlex
- 8.5.1. Overview & Patent Insight
- 8.5.2. Pricing & Dosage Insight
- 8.5.3. Sales Analysis
- 8.6. Terlivaz
- 8.6.1. Overview & Patent Insight
- 8.6.2. Pricing & Dosage Insight
- 8.6.3. Sales Analysis
- 8.7. Empaveli
- 8.7.1. Overview & Patent Insight
- 8.7.2. Pricing & Dosage Insight
- 8.7.3. Sales Analysis
- 8.8. Voxzogo
- 8.8.1. Overview & Patent Insight
- 8.8.2. Pricing & Dosage Insight
- 8.8.3. Sales Analysis
- 8.9. Imcivree
- 8.9.1. Overview & Patent Insight
- 8.9.2. Pricing & Dosage Insight
- 8.9.3. Sales Analysis
- 8.10. Trulicity
- 8.10.1. Overview & Patent Insight
- 8.10.2. Pricing & Dosage Insight
- 8.10.3. Sales Analysis
- 8.11. Ozempic
- 8.11.1. Overview & Patent Insight
- 8.11.2. Pricing & Dosage Insight
- 8.11.3. Sales Analysis
- 8.12. Wegovy
- 8.12.1. Overview & Patent Insight
- 8.12.2. Pricing & Dosage Insight
- 8.12.3. Sales Analysis
- 8.13. Tresiba
- 8.13.1. Overview & Patent Insight
- 8.13.2. Pricing & Dosage Insight
- 8.13.3. Sales Analysis
- 8.14. Rybelsus
- 8.14.1. Overview & Patent Insight
- 8.14.2. Pricing & Dosage Insight
- 8.14.3. Sales Analysis
- 8.15. Xultophy
- 8.15.1. Overview & Patent Insight
- 8.15.2. Pricing & Dosage Insight
- 8.15.3. Sales Analysis
- 8.16. Victoza
- 8.16.1. Overview & Patent Insight
- 8.16.2. Pricing & Dosage Insight
- 8.16.3. Sales Analysis
- 8.17. Ryzodeg
- 8.17.1. Overview & Patent Insight
- 8.17.2. Pricing & Dosage Insight
- 8.17.3. Sales Analysis
- 8.18. Fiasp
- 8.18.1. Overview & Patent Insight
- 8.18.2. Pricing & Dosage Insight
- 8.18.3. Sales Analysis
- 8.19. Lantus
- 8.19.1. Overview & Patent Insight
- 8.19.2. Pricing & Dosage Insight
- 8.19.3. Sales Analysis
- 8.20. Toujeo
- 8.20.1. Overview & Patent Insight
- 8.20.2. Pricing & Dosage Insight
- 8.20.3. Sales Analysis
9. Peptide Therapeutics Development Technologies Platform
- 9.1. Biodrug Design Accelerator - Fujitsu/PeptiDream
- 9.2. T-Win® Technology - IO Biotech
- 9.3. Numatech - Numaferm
- 9.4. ProteinStudio - ProteinQure
- 9.5. The Magnifier NφΦ™ - Nuritas
- 9.6. PepPower - GenScript
- 9.7. Unnamed Peptide Platform - Zealand Pharma
- 9.8. PDPS (Peptide Discovery Platform System) - PeptiDream
- 9.9. Veneno Suite - Veneno Technologies
- 9.10. SmartDepot™ Technology - Peptron
- 9.11. Bicycles - Bicycle Therapeutics
- 9.12. RALA Technolgy - pHion Therapeutics
- 9.13. Discovery Platform - Orbit Discovery
- 9.14. Imotopes - Imcyse
- 9.15. Nautilus - Peptilogics
- 9.16. Swarm Intelligence 2.0 - Pepticom
- 9.17. streaMLine Platform - Gubra
- 9.18. Precision Endocrine Peptides (PEPs) - MBX Biosciences
- 9.19. pHLIP (pH-Low Insertion Peptides) - pHLIP
- 9.20. alphalex - Cybrexa
10. Cyclic Peptides Clinical Trials Insight By Country, Indication & Phase
- 10.1. Research
- 10.2. Preclinical
- 10.3. Phase-I
- 10.4. Phase-I/II
- 10.5. Phase-II
- 10.6. Phase-II/III
- 10.7. Phase-III
- 10.8. Preregistration
- 10.9. Registered
- 10.10. Marketed
11. Peptide Hormones Clinical Trials Insight By Country, Indication & Phase
- 11.1. Research
- 11.2. Preclinical
- 11.3. Phase-I
- 11.5. Phase-I/II
- 11.6. Phase-II
- 11.7. Phase-II/III
- 11.8. Phase-III
- 11.9. Preregistration
- 11.10. Registered
- 11.11. Marketed
12. Peptides Clinical Trials Insight By Country, Indication & Phase
- 12.1. Research
- 12.2. Preclinical
- 12.3. Phase-I
- 12.4. Phase-I/II
- 12.5. Phase-II
- 12.6. Phase-II/III
- 12.7. Phase-III
- 12.8. Preregistration
- 12.9. Registered
- 12.10. Marketed
13. Glucagon-Like Peptides Clinical Trials Insight By Country, Indication & Phase
- 13.1. Preclinical
- 13.2. Phase-I
- 13.3. Phase-I/II
- 13.4. Phase-II
- 13.5. Phase-III
- 13.6. Marketed
14. Oligopeptides Clinical Trials Insight By Country, Indication & Phase
- 14.1. Research
- 14.2. Preclinical
- 14.3. Phase-I
- 14.4. Phase-I/II
- 14.5. Phase-II
- 14.6. Phase-II/III
- 14.7. Phase-III
- 14.8. Registered
- 14.9. Marketed
15. Lipopeptides Clinical Trials Insight By Country, Indication & Phase
- 15.1. Research
- 15.2. Preclinical
- 15.3. Phase-II
- 15.4. Marketed
16. Dipeptides Clinical Trials Insight By Country, Indication & Phase
- 16.1. Research
- 16.2. Preclinical
- 16.3. Phase-I
- 16.4. Phase-II
- 16.5. Phase-III
- 16.6. Registered
- 16.7. Marketed
17. Depsipeptides Clinical Trials Insight By Country, Indication & Phase
- 17.1. Preclinical
- 17.2. Phase-I
- 17.3. Phase-II
- 17.4. Marketed
18. Glycopeptides Clinical Trials Insight By Country, Indication & Phase
- 18.1. Preclinical
- 18.2. Phase-I
- 18.3. Phase-I/II
- 18.5. Phase-II
- 18.6. Phase-III
- 18.8. Marketed
19. Peptide Vaccines Clinical Trials Insight By Country, Indication & Phase
- 19.1. Preclinical
- 19.2. Phase-I/II
- 19.3. Phase-II
- 19.4. Phase-III
- 19.5. Registered
- 19.6. Marketed
20. Peptide Fragments Clinical Trials Insight By Country, Indication & Phase
- 20.1. Preclinical
- 20.2. Phase-I
- 20.3. Phase-II
- 20.4. Phase-III
- 20.5. Preregistration
- 20.6. Registered
- 20.7. Marketed
21. Opioid Peptides Clinical Trials Insight By Country, Indication & Phase
- 21.1. Research
- 21.2. Preclinical
- 21.3. Phase-I
- 21.4. Phase-II
- 21.5. Preregistration
- 21.6. Registered
- 21.7. Marketed
22. Natriuretic Peptides Clinical Trials Insight By Country, Indication & Phase
- 22.1. Preclinical
- 22.2. Phase-I
- 22.3. Phase-II
- 22.4. Phase-II/III
- 22.5. Phase-III
- 22.6. Marketed
23. Neuropeptides Clinical Trials Insight By Country, Indication & Phase
- 23.1. Research
- 23.2. Preclinical
- 23.3. Phase-I
- 23.4. Phase-I/II
- 23.5. Phase-II
- 23.6. Marketed
24. Antimicrobial Cationic Peptides Clinical Trials Insight By Country, Indication & Phase
- 24.1. Preclinical
- 24.2. Phase-I
- 24.3. Phase-III
25. Peptide Hydrolases Clinical Trials Insight By Country, Indication & Phase
- 25.1. Phase-II
26. Peptide Aptamers
- 26.1. Research
- 26.2. Preclinical
- 26.3. Phase-I
- 26.4. Phase-II
27. Intercellular Signalling Peptides Clinical Trials Insight By Country, Indication & Phase
- 27.1. Phase-II
28. Peptide Antibiotics Clinical Trials Insight By Country, Indication & Phase
- 28.1. Phase-I
29. Peptide Drug Conjugates Clinical Trials Insight By Country, Indication & Phase
- 29.1. Preclinical
30. Bicyclic Peptides Clinical Trials Insight By Country, Indication & Phase
- 30.1. Preclinical
31. Multiple Peptides Clinical Trials Insight By Country, Indication & Phase
- 31.1. Research
- 31.2. Preclinical
- 31.3. Phase-I
- 31.4. Phase-I/II
- 31.5. Phase-II
- 31.6. Preregistration
- 31.7. Registered
- 31.8. Marketed
32. Competitive Landscape
- 32.1. AbbVie
- 32.2. Adocia
- 32.3. Amgen
- 32.4. Antlia Bioscience
- 32.5. AsclepiX Therapeutics
- 32.6. AstraZeneca
- 32.7. Bicycle Therapeutics
- 32.8. Biohaven Labs
- 32.9. Bristol-Myers Squibb
- 32.10. Carmot Therapeutics
- 32.11. Eli Lilly and Company
- 32.12. Ferring Pharmaceuticals
- 32.13. Gan&Lee Pharmaceuticals
- 32.14. GEROPHARM
- 32.15. Hanmi Pharmaceutical
- 32.16. HEC Pharm
- 32.17. Heidelberg Pharma AG
- 32.18. ImCyse
- 32.19. Janux Therapeutics
- 32.20. Kine Sciences
- 32.21. Lactocore
- 32.22. Maxwell Biosciences
- 32.23. Merck & Co
- 32.24. Novartis
- 32.25. Novo Nordisk
- 32.26. Oryn Therapeutics
- 32.27. Palatin Technologies
- 32.28. PeptiDream
- 32.29. Pfizer
- 32.30. Priavoid
- 32.31. Primary Peptides
- 32.32. Protagonist Therapeutics
- 32.33. Roche
- 32.34. Sanofi
- 32.35. Sapience Therapeutics
- 32.36. Seagen
- 32.37. Shaanxi Micot Technology Co
- 32.38. Stuart Therapeutics
- 32.39. Takeda
- 32.40. Zealand Pharma
List of Figures
- Figure 1-1: Landmarks in Peptides Drugs Market
- Figure 3-1: Pro00013585 Phase II Study - Initiation & Completion Years
- Figure 3-2: STUDY0000567 Phase II Study - Initiation & Completion Years
- Figure 3-3: NCT05378672 Phase III Study - Initiation & Completion Years
- Figure 3-4: ZP4207-21052 Phase III Study - Initiation & Completion Years
- Figure 3-5: GLSI-21-01 Phase III Study - Initiation & Completion Years
- Figure 3-6: IO102-IO103-013 Phase III Study - Initiation & Completion Years
- Figure 3-7: NCT06091748 Phase II Study - Initiation & Completion Years
- Figure 3-8: PMC67199 Phase I Study - Initiation & Completion Years
- Figure 3-9: ACW-1221958-1 Phase II Study - Initiation & Completion Years
- Figure 3-10: NCT05841095 Phase I/II Study - Initiation & Completion Years
- Figure 3-11: NCT05340790 Phase I Study - Initiation & Completion Years
- Figure 3-12: IR902-007 Phase I Study - Initiation & Completion Years
- Figure 3-13: ISEMIS Phase I/II Study - Initiation & Completion Years
- Figure 3-14: YN011-301 Phase II/III Study - Initiation & Completion Years
- Figure 3-15: SCW0502-1031 Phase III Study - Initiation & Completion Years
- Figure 3-16: NCT05202353 Phase I Study - Initiation & Completion Years
- Figure 3-17: NCT04305002 Phase II Study - Initiation & Completion Years
- Figure 3-18: NCT05189210 Phase II Study - Initiation & Completion Years
- Figure 3-19: ALZ-C-001 Phase II Study - Initiation & Completion Years
- Figure 3-20: ELViS-FA Phase I/II Study - Initiation & Completion Years
- Figure 3-21: NCT05634876 Phase II Study - Initiation & Completion Years
- Figure 4-1: CUV104 Phase II Study - Initiation & Completion Years
- Figure 4-2: CUV152 Phase II Study - Initiation & Completion Years
- Figure 4-3: Peptide-Drug Conjugate Structure
- Figure 4-4: NCT04706962 Phase I Study - Initiation & Completion Years
- Figure 4-5: MLB-PK-001 Early Phase I Study - Initiation & Completion Year
- Figure 4-6: ANGLeD Phase III Study - Initiation & Completion Years
- Figure 4-7: CA209-8TX Phase I/II Study - Initiation & Completion Years
- Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study - Initiation & Completion Years
- Figure 4-9: COVENANT Phase III Study - Initiation & Completion Years
- Figure 4-10: EGRABIS1 Phase II Study - Initiation & Completion Years
- Figure 4-11: GLIMP Phase II Study - Initiation & Completion Years
- Figure 4-12: NCT05530577 Phase II Study - Initiation & Completion Years
- Figure 5-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
- Figure 5-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
- Figure 5-3: Ongoing Trends in Peptide Drugs Market
- Figure 5-4: Future Growth Avenues in Peptide Drugs Market
- Figure 6-1: China - Estimated Diabetes Population (Million), 2021 & 2030
- Figure 6-2: India - Estimated Diabetes Population (Million), 2021 & 2030
- Figure 6-3: ME - Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021 & 2030
- Figure 6-4: Canada - Estimated Diabetes Population (Million), 2021 & 2030
- Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
- Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
- Figure 7-3: Global - Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-4: Global - Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-5: Global - Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-6: Global - Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-7: Global - Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-8: Global - Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-9: Global - Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-10: Global - Depsipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-11: Global - Glycopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-12: Global - Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-13: Global - Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-14: Global - Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-15: Global - Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-16: Global - Neuropeptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-17: Global - Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-18: Global - Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till 2029
- Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till 2029
- Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till 2029
- Figure 8-1: US - Cost per Unit & Supply of Bylvay Oral Capsules (US$), November'2023
- Figure 8-2: US - Cost per Unit & Supply of Bylvay Oral Pellets (US$), November'2023
- Figure 8-3: EU - Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US$), November'2023
- Figure 8-4: Global - Quarterly Bylvay Sales (US$ Million), 2023
- Figure 8-5: NA - Quarterly Bylvay Sales (US$ Million), 2023
- Figure 8-6: Europe - Quarterly Bylvay Sales (US$ Million), 2023
- Figure 8-7: ROW - Quarterly Bylvay Sales (US$ Million), 2023
- Figure 8-8: Parsabiv - US Patents Expiration Years
- Figure 8-9: Parsabiv - Europe Patents Expiration Years
- Figure 8-10: Parsabiv - Cost per Unit & Supply (US$), November'2023
- Figure 8-11: Global - Annual Parsabiv Sales (US$ Million), 2019-2023
- Figure 8-12: US - Annual Parsabiv Sales (US$ Million), 2019-2023
- Figure 8-13: ROW - Annual Parsabiv Sales (US$ Million), 2019-2023
- Figure 8-14: Global - Quarterly Parsabiv Sales (US$ Million), 2023
- Figure 8-15: US - Quarterly Parsabiv Sales (US$ Million), 2023
- Figure 8-16: ROW - Quarterly Parsabiv Sales (US$ Million), 2023
- Figure 8-17: Global - Quarterly Parsabiv Sales (US$ Million), 2022
- Figure 8-18: US - Quarterly Parsabiv Sales (US$ Million), 2022
- Figure 8-19: ROW - Quarterly Parsabiv Sales (US$ Million), 2022
- Figure 8-20: Bydureon - Year of Approval and Expiry of Patents for Injection
- Figure 8-21: Bydureon - Year of Approval and Expiry of Patents for Injection
- Figure 8-22: Bydureon BCise - Cost per Unit & Supply (US$), November'2023
- Figure 8-23: Global - Annual Bydureon Sales (US$ Million), 2019-2023
- Figure 8-24: US - Annual Bydureon Sales (US$ Million), 2019-2023
- Figure 8-25: Europe - Annual Bydureon Sales (US$ Million), 2019-2023
- Figure 8-26: EM - Annual Bydureon Sales (US$ Million), 2019-2023
- Figure 8-27: ROW - Annual Bydureon Sales (US$ Million), 2019-2023
- Figure 8-28: Global - Quarterly Bydureon Sales (US$ Million), 2023
- Figure 8-29: US - Quarterly Bydureon Sales (US$ Million), 2023
- Figure 8-30: Europe - Quarterly Bydureon Sales (US$ Million), 2023
- Figure 8-31: EM - Quarterly Bydureon Sales (US$ Million), 2023
- Figure 8-32: Global - Quarterly Bydureon Sales (US$ Million), 2022
- Figure 8-33: US - Quarterly Bydureon Sales (US$ Million), 2022
- Figure 8-34: Europe - Quarterly Bydureon Sales (US$ Million), 2022
- Figure 8-35: EM - Quarterly Bydureon Sales (US$ Million), 2022
- Figure 8-36: Linzess - Cost per Unit & Supply (US$), November'2023
- Figure 8-37: Linzess - Dosage by Indication (mcg)
- Figure 8-38: Global - Annual Linzess Sales (US$ Million), 2020-2023
- Figure 8-39: US - Annual Linzess Sales (US$ Million), 2020-2023
- Figure 8-40: ROW - Annual Linzess Sales (US$ Million), 2019-2023
- Figure 8-41: Global - Quarterly Linzess Sales (US$ Million), 2023
- Figure 8-42: US - Quarterly Linzess Sales (US$ Million), 2023
- Figure 8-43: ROW - Quarterly Linzess Sales (US$ Million), 2023
- Figure 8-44: Global - Quarterly Linzess Sales (US$ Million), 2022
- Figure 8-45: US - Quarterly Linzess Sales (US$ Million), 2022
- Figure 8-46: ROW - Quarterly Linzess Sales (US$ Million), 2022
- Figure 8-47: Increlex - US & EU Patent Expiry Years
- Figure 8-48: Increlex - Cost per Unit & Supply (US$), November'2023
- Figure 8-49: Global - Annual Increlex Sales (US$ Million), 2019-2023
- Figure 8-50: Global - Quarterly Increlex Sales (US$ Million), 2023
- Figure 8-51: Global - Quarterly Increlex Sales (US$ Million), 2022
- Figure 8-52 : Terlivaz - Dosing Chart
- Figure 8-53: Global - Quarterly Terlivaz Sales (US$ Million), 2023
- Figure 8-54: Empaveli - Cost per Unit & Supply (US$), November'2023
- Figure 8-55: Empaveli - Cost of Monthly & Yearly Treatment (US$), November'2023
- Figure 8-56: Global - Annual Empaveli Sales (US$ Million), 2021-2023
- Figure 8-57: US - Annual Empaveli Sales (US$ Million), 2021-2023
- Figure 8-58: ROW - Annual Empaveli Sales (US$ Million), 2021-2023
- Figure 8-59: Global - Quarterly Increlex Sales (US$ Million), 2023
- Figure 8-60: US - Quarterly Empaveli Sales (US$ Million), 2023
- Figure 8-61: ROW - Quarterly Empaveli Sales (US$ Million), 2023
- Figure 8-62: Global - Quarterly Increlex Sales (US$ Million), 2022
- Figure 8-63: US - Annual Empaveli Sales (US$ Million), 2022
- Figure 8-64: ROW - Annual Empaveli Sales (US$ Million), 2022
- Figure 8-65: Voxzogo - Cost per Unit & Supply (US$), November'2023
- Figure 8-66: Global - Annual Voxzogo Sales (US$ Million), 2021-2023
- Figure 8-67: Global - Quarterly Voxzogo Sales (US$ Million), 2023
- Figure 8-68: Global - Quarterly Voxzogo Sales (US$ Million), 2022
- Figure 8-69: Global - Annual Imcivree Sales (US$ Million), 2021-2023
- Figure 8-70: Global - Quarterly Imcivree Sales (US$ Million), 2023
- Figure 8-71: Global - Quarterly Imcivree Sales (US$ Million), 2022
- Figure 8-72: Voxzogo - Cost per Unit & Supply (US$), November'2023
- Figure 8-73: Global - Annual Trulicity Sales (US$ Million), 2019-2023
- Figure 8-74: Global - Quarterly Trulicity Sales (US$ Million), 2023
- Figure 8-75: Global - Quarterly Trulicity Sales (US$ Million), 2022
- Figure 8-76: Ozempic - Cost per Unit & Supply (US$), November'2023
- Figure 8-77: Ozempic - Initiation and Increment Doses (mg/week)
- Figure 8-78: Global - Annual Ozempic Sales (US$ Million), 2019-2023
- Figure 8-79: NA - Annual Ozempic Sales (US$ Million), 2019-2023
- Figure 8-80: EMEA - Annual Ozempic Sales (US$ Million), 2019-2023
- Figure 8-81: China - Annual Ozempic Sales (US$ Million), 2019-2023
- Figure 8-82: ROW - Annual Ozempic Sales (US$ Million), 2019-2023
- Figure 8-83: Global - Quarterly Ozempic Sales (US$ Million), 2023
- Figure 8-84: NA - Quarterly Ozempic Sales (US$ Million), 2023
- Figure 8-85: EMEA - Quarterly Ozempic Sales (US$ Million), 2023
- Figure 8-86: China - Quarterly Ozempic Sales (US$ Million), 2023
- Figure 8-87: ROW - Quarterly Ozempic Sales (US$ Million), 2023
- Figure 8-88: Global - Quarterly Ozempic Sales (US$ Million), 2022
- Figure 8-89: NA - Quarterly Ozempic Sales (US$ Million), 2022
- Figure 8-90: EMEA - Quarterly Ozempic Sales (US$ Million), 2022
- Figure 8-91: China - Quarterly Ozempic Sales (US$ Million), 2022
- Figure 8-92: ROW - Quarterly Ozempic Sales (US$ Million), 2022
- Figure 8-93: Wegovy - Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions (US$), November'2023
- Figure 8-94: Wegovy - Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US$), November'2023
- Figure 8-95: Global - Annual Wegovy Sales (US$ Million), 2021-2023
- Figure 8-96: NA - Annual Wegovy Sales (US$ Million), 2021-2023
- Figure 8-97: EMEA - Annual Wegovy Sales (US$ Million), 2021-2023
- Figure 8-98: Global - Quarterly Wegovy Sales (US$ Million), 2023
- Figure 8-99: NA - Quarterly Wegovy Sales (US$ Million), 2023
- Figure 8-100: EMEA - Quarterly Wegovy Sales (US$ Million), 2023
- Figure 8-101: Global - Quarterly Wegovy Sales (US$ Million), 2022
- Figure 8-102: NA - Quarterly Wegovy Sales (US$ Million), 2022
- Figure 8-103: EMEA - Quarterly Wegovy Sales (US$ Million), 2022
- Figure 8-104: Tresiba - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
- Figure 8-105: Tresiba - Cost per Unit & Supply of 200 units/mL Solution (US$), November'2023
- Figure 8-106: Insulin degludec - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
- Figure 8-107: Global - Annual Tresiba Sales (US$ Million), 2019-2023
- Figure 8-108: NA - Annual Tresiba Sales (US$ Million), 2019-2023
- Figure 8-109: EMEA - Annual Tresiba Sales (US$ Million), 2019-2023
- Figure 8-110: China - Annual Tresiba Sales (US$ Million), 2019-2023
- Figure 8-111: ROW - Annual Tresiba Sales (US$ Million), 2019-2023
- Figure 8-112: Global - Quarterly Tresiba Sales (US$ Million), 2023
- Figure 8-113: NA - Quarterly Tresiba Sales (US$ Million), 2023
- Figure 8-114: EMEA - Quarterly Tresiba Sales (US$ Million), 2023
- Figure 8-115: China - Quarterly Tresiba Sales (US$ Million), 2023
- Figure 8-116: ROW - Quarterly Tresiba Sales (US$ Million), 2023
- Figure 8-117: Global - Quarterly Tresiba Sales (US$ Million), 2022
- Figure 8-118: NA - Quarterly Tresiba Sales (US$ Million), 2022
- Figure 8-119: EMEA - Quarterly Tresiba Sales (US$ Million), 2022
- Figure 8-120: China - Quarterly Tresiba Sales (US$ Million), 2022
- Figure 8-121: ROW - Quarterly Tresiba Sales (US$ Million), 2022
- Figure 8-122: Rybelsus - Cost per Unit & Supply (US$), November'2023
- Figure 8-123: Global - Annual Rybelsus Sales (US$ Million), 2019-2023
- Figure 8-124: NA - Annual Rybelsus Sales (US$ Million), 2019-2023
- Figure 8-125: EMEA - Annual Rybelsus Sales (US$ Million), 2019-2023
- Figure 8-126: China - Annual Rybelsus Sales (US$ Million), 2019-2023
- Figure 8-127: ROW - Annual Rybelsus Sales (US$ Million), 2019-2023
- Figure 8-128: Global - Quarterly Rybelsus Sales (US$ Million), 2023
- Figure 8-129: NA - Quarterly Rybelsus Sales (US$ Million), 2023
- Figure 8-130: EMEA - Quarterly Rybelsus Sales (US$ Million), 2023
- Figure 8-131: China - Quarterly Rybelsus Sales (US$ Million), 2023
- Figure 8-132: ROW - Quarterly Rybelsus Sales (US$ Million), 2023
- Figure 8-133: Global - Quarterly Rybelsus Sales (US$ Million), 2022
- Figure 8-134: NA - Quarterly Rybelsus Sales (US$ Million), 2022
- Figure 8-135: EMEA - Quarterly Rybelsus Sales (US$ Million), 2022
- Figure 8-136: China - Quarterly Rybelsus Sales (US$ Million), 2022
- Figure 8-137: ROW - Quarterly Rybelsus Sales (US$ Million), 2022
- Figure 8-138: Xultophy - Cost per Unit & Supply (US$), November'2023
- Figure 8-139: Global - Annual Xultophy Sales (US$ Million), 2019-2023
- Figure 8-140: NA - Annual Xultophy Sales (US$ Million), 2019-2023
- Figure 8-141: EMEA - Annual Xultophy Sales (US$ Million), 2019-2023
- Figure 8-142: China - Annual Xultophy Sales (US$ Million), 2019-2023
- Figure 8-143: ROW - Annual Xultophy Sales (US$ Million), 2019-2023
- Figure 8-144: Global - Quarterly Xultophy Sales (US$ Million), 2023
- Figure 8-145: NA - Quarterly Xultophy Sales (US$ Million), 2023
- Figure 8-146: EMEA - Quarterly Xultophy Sales (US$ Million), 2023
- Figure 8-147: China - Quarterly Xultophy Sales (US$ Million), 2023
- Figure 8-148: ROW - Quarterly Xultophy Sales (US$ Million), 2023
- Figure 8-149: Global - Quarterly Xultophy Sales (US$ Million), 2022
- Figure 8-150: NA - Quarterly Xultophy Sales (US$ Million), 2022
- Figure 8-151: EMEA - Quarterly Xultophy Sales (US$ Million), 2022
- Figure 8-152: China - Quarterly Xultophy Sales (US$ Million), 2022
- Figure 8-153: ROW - Quarterly Xultophy Sales (US$ Million), 2022
- Figure 8-154: Victoza - Cost per Unit & Supply (US$), November'2023
- Figure 8-155: Global - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-156: North America - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-157: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-158: China - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-159: ROW - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-160: Global - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-161: North America - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-162: EMEA - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-163: China - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-164: ROW - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-165: Global - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-166: North America - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-167: EMEA - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-168: China - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-169: ROW - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-170: Global - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-171: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-172: China - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-173: ROW - Annual Victoza Sales (US$ Million), 2019-2023
- Figure 8-174: Global - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-175: EMEA - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-176: China - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-177: ROW - Quarterly Victoza Sales (US$ Million), 2023
- Figure 8-178: Global - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-179: EMEA - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-180: China - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-181: ROW - Quarterly Victoza Sales (US$ Million), 2022
- Figure 8-182: Fiasp - Cost per Unit & Supply (US$), November'2023
- Figure 8-183: Global - Annual Fiasp Sales (US$ Million), 2019-2023
- Figure 8-184: NA - Annual Fiasp Sales (US$ Million), 2019-2023
- Figure 8-185: EMEA - Annual Fiasp Sales (US$ Million), 2019-2023
- Figure 8-186: ROW - Annual Fiasp Sales (US$ Million), 2019-2023
- Figure 8-187: Global - Quarterly Fiasp Sales (US$ Million), 2023
- Figure 8-188: NA - Quarterly Fiasp Sales (US$ Million), 2023
- Figure 8-189: EMEA - Quarterly Fiasp Sales (US$ Million), 2023
- Figure 8-190: ROW - Quarterly Fiasp Sales (US$ Million), 2023
- Figure 8-191: Global - Quarterly Fiasp Sales (US$ Million), 2022
- Figure 8-192: NA - Quarterly Fiasp Sales (US$ Million), 2022
- Figure 8-193: EMEA - Quarterly Fiasp Sales (US$ Million), 2022
- Figure 8-194: ROW - Quarterly Fiasp Sales (US$ Million), 2022
- Figure 8-195: Lantus - Cost per Unit & Supply (US$), November'2023
- Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn - Cost per Unit & Supply (US$), November'2023
- Figure 8-197: Global - Annual Lantus Sales (US$ Million), 2019-2023
- Figure 8-198: US - Annual Lantus Sales (US$ Million), 2019-2023
- Figure 8-199: Europe - Annual Lantus Sales (US$ Million), 2019-2023
- Figure 8-200: ROW - Annual Lantus Sales (US$ Million), 2019-2023
- Figure 8-201: Global - Quarterly Lantus Sales (US$ Million), 2023
- Figure 8-202: US - Quarterly Lantus Sales (US$ Million), 2023
- Figure 8-203: Europe - Quarterly Lantus Sales (US$ Million), 2023
- Figure 8-204: ROW - Quarterly Lantus Sales (US$ Million), 2023
- Figure 8-205: Global - Quarterly Lantus Sales (US$ Million), 2022
- Figure 8-206: US - Quarterly Lantus Sales (US$ Million), 2022
- Figure 8-207: Europe - Quarterly Lantus Sales (US$ Million), 2022
- Figure 8-208: ROW - Quarterly Lantus Sales (US$ Million), 2022
- Figure 8-209: Toujeo - US Patent Acceptance & Expiration Years
- Figure 8-210: Toujeo - Cost per Unit & Supply (US$), November'2023
- Figure 8-211: Global - Annual Toujeo Sales (US$ Million), 2019-2023
- Figure 8-212: US - Annual Toujeo Sales (US$ Million), 2019-2023
- Figure 8-213: Europe - Annual Toujeo Sales (US$ Million), 2019-2023
- Figure 8-214: ROW - Annual Toujeo Sales (US$ Million), 2019-2023
- Figure 8-215: Global - Quarterly Toujeo Sales (US$ Million), 2023
- Figure 8-216: US - Quarterly Toujeo Sales (US$ Million), 2023
- Figure 8-217: Europe - Quarterly Toujeo Sales (US$ Million), 2023
- Figure 8-218: ROW - Quarterly Toujeo Sales (US$ Million), 2023
- Figure 8-219: Global - Quarterly Toujeo Sales (US$ Million), 2022
- Figure 8-220: US - Quarterly Toujeo Sales (US$ Million), 2022
- Figure 8-221: Europe - Quarterly Toujeo Sales (US$ Million), 2022
- Figure 8-222: ROW - Quarterly Toujeo Sales (US$ Million), 2022
- Figure 9-1: Biodrug Design Accelerator - Technical Benefits
- Figure 9-2: Biodrug Design Accelerator - Technical Benefits
- Figure 9-3: IO Biotech - T-win Technology
- Figure 9-4: Numatech - Numaferm Platform
- Figure 9-5: Nuritas - Scientific Achievements of Magnifier NφΦ Bioactive Peptide Discovery Platform
- Figure 9-6: Nuritas - The Magnifier NφΦ Bioactive Peptide Discovery Process
- Figure 9-7: Nuritas - The Magnifier NφΦ Bioactive Peptide Results
- Figure 9-8: GenScript - PepPower Technology
- Figure 9-9: PeptiDream - PDPS Outline
- Figure 9-10: PeptiDream - PDPS Outline
- Figure 9-11: PeptiDream - PDPS Features
- Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
- Figure 9-13: Veneno Technologies - Veneno Suite Components
- Figure 9-14: Veneno Technologies - Veneno Suite Process
- Figure 9-15: Peptron - SmartDepot™ Features
- Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
- Figure 9-17: Bicycle Therapeutics - Bicycles Key Properties
- Figure 9-18: Bicycle Therapeutics - Bicycles Key Properties
- Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
- Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
- Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
- Figure 9-22: Benefits of Imotopes over Current Therapies
- Figure 9-23: Peptilogics - Peptide Development Process
- Figure 9-24: Peptilogics - Nautilus Features
- Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
- Figure 9-26: Cybrexa - alphalex Selective Tumor Cell Targeting
List of Tables
- Table 1-1: Landmarks in Peptides Drugs Market
- Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
- Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
- Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum Calcium and Parathyroid Hormone Levels during Treatment
- Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
- Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
- Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older
- Table 9-1: GenScript - PepPower™ Platform Advantages
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.